Galapagos is a clinical-stage biotechnology company, specialised in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focussed on delivering innovative medicines that will improve people's lives.
Onno van de Stolpe, Galapagos CEO, discusses what the concept of "thinking big" means to him.
Using our unique target and discovery technology platform, we are progressing one of biotech’s largest pipelines of medicines with novel modes of action.
With our vast bank of proprietary knowledge on disease biology, we are increasing the chances of bringing more treatments to the market and to patients.
We have nurtured a potent culture of fearlessness and commitment at Galapagos. As individuals, as teams and as a company, we are empowered to make bold decisions, take risks, challenge ourselves and embrace change.
It means we go where no one has been before, following the science in swift, relentless pursuit of improving patient outcomes. It means we push the boundaries of what we know and think is possible.
By discovering and developing medicines that tackle the disease itself and not just moderate its symptoms, we are working towards delivering effective solutions for patients.
The innovative therapies we plan to deliver will address large areas of unmet medical needs, improve patients' lives and make a lasting positive contribution to society.